Neha Vagadia in Voorhees, New Jersey

Additional Medical Specialties Include:
CRITICAL CARE (INTENSIVISTS)

Medical School: New York College Of Osteo Medicine Of New York Institute Of Technology
Graduation Year: 2004
The Primary Medical Specialty for Neha Vagadia is listed as: Pulmonary Disease
Approximate Years of Experience: 20
PAC (PECOS ID)#: 4981869732
NPI #: 1649326463
NPI Created On: 01/26/2007
NPI Last Updated Listed as: 04/15/2022
Primary Taxonomy Code: 207R00000X
License Number:
221565
Listed Gender: Female

Forms of insurance accepted by include, but are not limited to:

• AmeriHealth New Jersey
• Blue Cross Blue Shield
• Humana
• Oscar Garden State Insurance Corporation
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration
2. Determination of lung volumes using gas dilution or washout
3. Measurement of lung diffusing capacity
4. New patient office or other outpatient visit, typically 30 minutes
5. New patient office or other outpatient visit, typically 45 minutes
6. Established patient office or other outpatient visit, typically 15 minutes
7. Established patient office or other outpatient, visit typically 25 minutes
8. Initial hospital inpatient care, typically 50 minutes per day
9. Initial hospital inpatient care, typically 70 minutes per day
10. Subsequent hospital inpatient care, typically 25 minutes per day
11. Subsequent hospital inpatient care, typically 35 minutes per day
12. Critical care delivery critically ill or injured patient, first 30-74 minutes
13. Physician telephone patient service, 11-20 minutes of medical discussion
14. Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic
15. Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg